{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:18:32Z","timestamp":1789582712986,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.biopha.2020.110410","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T23:20:39Z","timestamp":1592608839000},"page":"110410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor"],"prefix":"10.1016","volume":"129","author":[{"given":"Jingchao","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaijie","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2020.110410_bib0005","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110410_bib0010","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"I. Valsartan Heart Failure Trial. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110410_bib0015","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110410_bib0020","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110410_bib0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00395-004-0457-8","article-title":"The natriuretic peptides","volume":"99","author":"Baxter","year":"2004","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.biopha.2020.110410_bib0030","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ajh.2008.174","article-title":"Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases","volume":"21","author":"Rubattu","year":"2008","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.biopha.2020.110410_bib0035","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","article-title":"Long-term neprilysin inhibition - implications for ARNIs","volume":"14","author":"Campbell","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.biopha.2020.110410_bib0040","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/01.HYP.0000054215.71691.16","article-title":"Vasopeptidase inhibition: a double-edged sword?","volume":"41","author":"Campbell","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2020.110410_bib0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.biopha.2020.110410_bib0050","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s002280050196","article-title":"Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure","volume":"51","author":"Kentsch","year":"1996","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110410_bib0055","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2020.110410_bib0060","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.biopha.2020.110410_bib0065","series-title":"Angiotensin II Receptor Antagonist Metabolite and NEP Inhibitor Composite, and Preparation Method Thereof","author":"Yan","year":"2017"},{"key":"10.1016\/j.biopha.2020.110410_bib0070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00004872-199302000-00007","article-title":"EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells","volume":"11","author":"Sachinidis","year":"1993","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2020.110410_bib0075","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1021\/jm00010a014","article-title":"Dicarboxylic acid dipeptide neutral endopeptidase inhibitors","volume":"38","author":"Ksander","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2020.110410_bib0080","article-title":"Echocardiographic evaluation of cardiac function in ischemic rats: value of m-mode echocardiography","volume":"3","author":"Darbandi Azar","year":"2014","journal-title":"Res. Cardiovasc. Med."},{"key":"10.1016\/j.biopha.2020.110410_bib0085","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1152\/japplphysiol.01154.2010","article-title":"Echocardiographic detection of congestive heart failure in postinfarction rats","volume":"111","author":"Martinez","year":"2011","journal-title":"J. Appl. Physiol. (1985)"},{"key":"10.1016\/j.biopha.2020.110410_bib0090","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bph.14153","article-title":"Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers","volume":"175","author":"Curtis","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110410_bib0095","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2020.110410_bib0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pharmthera.2014.05.002","article-title":"Current role of neprilysin inhibitors in hypertension and heart failure","volume":"144","author":"von Lueder","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2020.110410_bib0105","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jash.2017.04.012","article-title":"Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril\/valsartan","volume":"11","author":"Chrysant","year":"2017","journal-title":"J. Am. Soc. Hypertens."},{"key":"10.1016\/j.biopha.2020.110410_bib0110","first-page":"157","article-title":"Preparation and characterization of self-microemulsifying drug delivery system of carvedilol","volume":"7","author":"Ramkath","year":"2016","journal-title":"Int J Res Pharm Sci."},{"key":"10.1016\/j.biopha.2020.110410_bib0115","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/00498254.2017.1295171","article-title":"Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition","volume":"48","author":"Hanna","year":"2018","journal-title":"Xenobiotica"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222030603X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222030603X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:03:09Z","timestamp":1760097789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222030603X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":23,"alternative-id":["S075333222030603X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110410","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110410"}}